Bloomberg Law  |  September 25, 2020

“If Justice Ginsburg had stayed on the bench, the assumption was that the ACA would be upheld,” said Katie Keith, a professor at Georgetown Law. “If we’re in a world where biosimilars were gone it raises more questions than we have answers,” Keith said. “What about the products already approved? What about products waiting in the pipeline? How would the FDA approach the regulatory uncertainty that this would unleash?” Keith said. “It could be severely disruptive. It would be a free fall.”

Read more here.